Drugs / GNX102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04250597 | Jul 2020 → Jul 2023 | metastatic malignant neoplasm | GlycoNex, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GNX102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04250597 ↗ |
| Modality | Monoclonal antibody | “GNX102 is a humanized monoclonal antibody (mAb)” NCT04250597 ↗ |